USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Equities research analysts at DA Davidson issued their Q2 2024 earnings estimates for USANA Health Sciences in a research note issued to investors on Tuesday, May 7th. DA Davidson analyst L. Weiser expects that the company will post earnings of $0.68 per share for the quarter. DA Davidson currently has a "Neutral" rating and a $46.00 target price on the stock. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.75 per share.
Separately, StockNews.com upgraded USANA Health Sciences from a "buy" rating to a "strong-buy" rating in a research report on Friday, January 12th.
Read Our Latest Report on USNA
USANA Health Sciences Price Performance
Shares of USNA stock traded up $0.28 during midday trading on Wednesday, reaching $45.02. 75,366 shares of the company traded hands, compared to its average volume of 81,431. The firm's 50 day simple moving average is $46.48 and its two-hundred day simple moving average is $48.07. The firm has a market cap of $864.38 million, a PE ratio of 14.02, a price-to-earnings-growth ratio of 1.38 and a beta of 0.94. USANA Health Sciences has a 1-year low of $41.45 and a 1-year high of $69.60.
USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings data on Tuesday, February 6th. The company reported $0.87 EPS for the quarter, topping analysts' consensus estimates of $0.52 by $0.35. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.80%. The firm had revenue of $221.08 million for the quarter, compared to the consensus estimate of $206.70 million.
Hedge Funds Weigh In On USANA Health Sciences
Large investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. lifted its holdings in shares of USANA Health Sciences by 75.7% during the 4th quarter. Pacer Advisors Inc. now owns 337,371 shares of the company's stock valued at $18,083,000 after acquiring an additional 145,373 shares in the last quarter. West Coast Financial LLC acquired a new stake in shares of USANA Health Sciences in the 3rd quarter worth about $2,469,000. Vanguard Group Inc. lifted its position in USANA Health Sciences by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,567,182 shares of the company's stock valued at $91,853,000 after purchasing an additional 38,533 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in USANA Health Sciences by 58.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 82,199 shares of the company's stock valued at $3,987,000 after purchasing an additional 30,485 shares during the period. Finally, Pzena Investment Management LLC raised its holdings in shares of USANA Health Sciences by 3.1% during the first quarter. Pzena Investment Management LLC now owns 785,344 shares of the company's stock valued at $38,089,000 after buying an additional 23,729 shares during the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In other news, COO Walter Noot sold 5,240 shares of the business's stock in a transaction on Friday, March 8th. The stock was sold at an average price of $49.05, for a total value of $257,022.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other USANA Health Sciences news, insider David Mulham Mulham sold 4,311 shares of USANA Health Sciences stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $47.76, for a total value of $205,893.36. Following the completion of the sale, the insider now directly owns 7,825 shares of the company's stock, valued at approximately $373,722. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Walter Noot sold 5,240 shares of the firm's stock in a transaction on Friday, March 8th. The stock was sold at an average price of $49.05, for a total value of $257,022.00. The disclosure for this sale can be found here. Insiders have sold 34,286 shares of company stock worth $1,634,010 over the last ninety days. 0.33% of the stock is currently owned by insiders.
About USANA Health Sciences
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Recommended Stories
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
